By Robert Dillard
A new drug developed to treat cancers with an altered BRAF gene has shown efficacy in an early patient trial, according to a study presented at the 32nd EORTC-NCI-AACR  Symposium on Molecular Targets and Cancer Therapeutics, … Read more
By Anne Harding
New findings debunk the conventional wisdom that Black cancer patients are less likely to agree to participate in clinical trials.
Overall, 55% of patients offered trial participation agreed to enroll, and white and Black patients agreed to … Read more
By Angus Liu
Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more
CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients, has named the winners of its Third Annual Ovarian Cancer Heroes® awards program. The virtual celebration will be held Friday, … Read more
By Savannah Demko
Triple therapy with olaparib plus durvalumab and bevacizumab were well-tolerated in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer, according to data presented at ESMO Virtual Congress 2020.
“Preclinical studies suggest the potential for synergy between … Read more
Researchers have seen promising results by injecting dog and mouse tumors with the cowpea mosaic virus. Now they’re aiming for a human trial.
By Daniel Oberhaus
Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.
The … Read more
By Matthew Fowler
xCures recently announced that the FDA granted its IND immediate Expanded Access Program for the ERK inhibitor ulixertinib to treat patients with MAPK pathway aberrant cancer.
The FDA granted the investigational new drug application for the ERK
By Liam Drew
PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more
No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab.
By Charles Bankhead
An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.… Read more
Patients with BRCA1/2 mutations are at higher risk for breast, ovarian and prostate cancers that can be aggressive when they develop—and, in many cases, resistant to lifesaving drugs. Now scientists at The University of Texas at Austin and Ajou University … Read more
Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more
Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more
The World Ovarian Cancer Coalition has designated The Clearity Foundation as a Champion of the newly launched Global Ovarian Cancer Charter which seeks to improve survival and quality of life for women diagnosed with ovarian cancer through the implementation of … Read more
When a loved one is diagnosed with ovarian cancer, it has a profound effect on their lives and their families’ lives. As quickly as the patient receives her diagnosis, her family members immediately slip into caregivers’ roles, often without warning … Read more
By Leah Lawrence
A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more
By Susan Moench, PhD, PA-C
Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more